MLchartDataset catalogue

anti-CALRmut/anti-CD3 bispecific antibody JNJ-88549968

Term · Oncology and biomedicine · MLC-T-ONC-010197

A bispecific antibody directed against both the mutated form of calreticulin (CALRmut; mutCALR) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CALRmut/anti-CD3 bispecific antibody JNJ-88549968 targets and binds to both CALRmut expressed on CALR mutated CD34-positive hematopoietic stem cells (HSCs) and CD3 on T cells. This results in the cross-linking of CALRmut-expressing tumor cells and T cells, and induces a cytotoxic T-lymphocyte (CTL) response against CALRmut-expressing tumor cells. CALR mutations, either insertions or deletions in exon 9, result in a frameshift that causes the loss of the KDEL ER retention motif. CALR mutations drive a variety of myeloproliferative neoplasms (MPNs).

Table 1. Record
IdentifierMLC-T-ONC-010197
FieldOncology and biomedicine
Synonymsanti-CALRmut/CD3 bispecific antibody JNJ-88549968; anti-mutant calreticulin/anti-CD3 bispecific antibody JNJ-88549968; CALRmutxCD3 T-cell redirecting antibody JNJ-88549968
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010197",
  "term": "anti-CALRmut/anti-CD3 bispecific antibody JNJ-88549968",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody directed against both the mutated form of calreticulin (CALRmut; mutCALR) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CALRmut/anti-CD3 bispecific antibody JNJ-88549968 targets and binds to both CALRmut expressed on CALR mutated CD34-positive hematopoietic stem cells (HSCs) and CD3 on T cells. This results in the cross-linking of CALRmut-expressing tumor cells and T cells, and induces a cytotoxic T-lymphocyte (CTL) response against CALRmut-expressing tumor cells. CALR mutations, either insertions or deletions in exon 9, result in a frameshift that causes the loss of the KDEL ER retention motif. CALR mutations drive a variety of myeloproliferative neoplasms (MPNs).",
  "synonyms": [
    "anti-CALRmut/CD3 bispecific antibody JNJ-88549968",
    "anti-mutant calreticulin/anti-CD3 bispecific antibody JNJ-88549968",
    "CALRmutxCD3 T-cell redirecting antibody JNJ-88549968"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-calrmut-anti-cd3-bispecific-antibody-jnj-88549968/"
}

Record 1,278 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.